Physical activity and cancer
Journal Title: OncoReview - Year 2012, Vol 2, Issue 4
Abstract
Physical activity has been shown to decrease the incidence of breast and colon cancers and most likely of cancers of the prostate, endometrium and lung. The mechanism of this effect is very complex and not completely understood. Physical activity has an impact on the immune system (increased number of natural killer (NK) cells and cytotoxic T cells), may reduce inflammation (significantly decreased plasma TNF-α, IL-6, and CRP), has effects on sex hormones (decreased bioavailability of estrogens and increased concentration of sex hormone-binding globulin) and influences insulin metabolism. Recent publications have shown that physical activity after cancer diagnosis and treatment is associated with reduced risk of breast and colon cancer recurrence and increases the survival rates (40% to 50% lower risk of cancer death). It is therefore important to encourage patients to physical activity. American Cancer Society has given recommendation for moderate exercise for at least 30, or better 45–60 min, on at least 5 days per week.
Authors and Affiliations
Maria Litwiniuk , Izabela Kara
Keywords
Related Articles
- EP ID EP53177
- DOI -
- Views 256
- Downloads 0
Retrospective assessment of everolimus treatment in patients suffering from advanced renal cell carcinoma
Objective: Results of second-line everolimus treatment in clear cell renal carcinoma. Material and methods: Clinical data of 32 patients of the Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria...
IgM multiple myeloma: diagnostic difficulties and results of bortezomib treatment – case report
The IgM paraprotein secretion is most frequently associated with Waldenström’s macroglobulinemia. In very rare cases it may also occur in multiple myeloma. The diagnostic and therapeutic process of a 84 year old male suf...
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metas...
Nadciśnienie tętnicze indukowane terapią sunitinibem
Nadciśnienie tętnicze jest częstą chorobą współistniejącą u chorych na raka nerki oraz częstym powikłaniem terapii sunitinibem. Blokowanie szlaku zależnego od VEGF prowadzi do dysfunkcji śródbłonka, zmniejszenia wytwarza...
Znaczenie badań molekularnych w kwalifikacji do terapii I linii erlotynibem chorych na NDRP na podstawie wyników badania EURTAC
W latach 2010–2011 pierwszy inhibitor kinazy tyrozynowej EGFR (IKT EGFR) – gefitynib uzyskał w wielu krajach rejestrację do leczenia w I linii chorych na zaawansowanego i miejscowo zaawansowanego niedrobnokomórkowego rak...